Abstract
Interstitial pneumonitis has been described infrequently following administration of docetaxel, used alone or in combination with other chemotherapeutic agents or concurrent irradiation, for non-small-cell lung cancer (NSCLC). This toxicity is of special relevance in NSCLC, as clinical severity and differential diagnosis may be especially challenging. It seems to be due to type I and type IV hypersensitivity reactions to the drug. Clinical and radiographic features are nonspecific and diagnosis is made by exclusion. The rate of grade III–IV docetaxel-induced pneumonitis, ranging from 7 to 47%, depends on several factors, including total dose, chemotherapy schedule and especially concomitant docetaxel treatment with gemcitabine and radiotherapy. Although the usual outcome is cure, it sometimes eventually progresses to pulmonary fibrosis despite steroid treatment. This toxicity must be taken into account when planning treatment strategies for NSCLC in order to reduce its rate and to achieve prompt diagnosis and treatment.
Article PDF
Similar content being viewed by others
Avoid common mistakes on your manuscript.
References
Stover DE, Kaner JR (2005) Pulmonary toxicity. In: DeVita VT, Hellman S, Rosenberg SA (eds) Cancer principles and practice of oncology, 7th Edn. Lippincott Williams and Wilkins, Philadelphia, pp 2535–2545
(2006) Interstitial pneumonia in Taxotere. In: Micromedex. Healthcare series. Available at: http://www.micromedex.com
(2006) Taxane-induced pulmonary toxicity. UptoDate version 14.3. Available at: http://www.uptodate.com
Karakan O, Eyuboglu FO, Akcay S, Ozylkan O (2004) Acute interstitial pneumopathy associated with docetaxel hypersensitivity. Onkologie 27:563–565
Karasawa K, Katsui K, Seki K et al (2003) Radiotherapy with concurrent docetaxel for advanced and recurrent breast cancer. Breast Cancer 10:268–274
Behrens RJ, Gulley JL, Dahut WL (2003) Pulmonary toxicity during prostate cancer treatment with docetaxel and thalidomide. Am J Ther 10:228–232
Dunsford ML, Mead GM, Bateman AC et al (1999) Severe pulmonary toxicity in patients treated with a combination of docetaxel and gemcitabine for metastatic transitional cell carcinoma. Ann Oncol 10:943–947
Read WL, Mortimer JE, Picus J (2002) Severe interstitial pneumonitis associated with docetaxel administration. Cancer 94:847–853
Etienne B, Perol M, Nesme P et al (1998) Acute diffuse interstitial pneumopathy following docetaxel. A propos of 2 cases. Rev Mal Respir 15:199–203
Wang GS, Yang KY, Perng RP (2001) Life-threatening hypersensitivity pneumonitis induced by docetaxel. Br J Cancer 85:1247–1250
Chen YM, Shih JF, Lee CS et al (2003) Phase II study of docetaxel and ifosfamide combination chemotherapy in non-small cell lung cancer patients failing previous chemotherapy with or without paclitaxel. Lung Cancer 39:209–214
Hainsworth JD, Burris HA, Greco FA (2001) Weekly docetaxel as a single agent and in combination with gemcitabine in elderly and poor performance status patients with advanced non-small cell lung cancer. Semin Oncol 28:21–25
Chen YM, Perg RP, Lin WC et al (2002) Phase II study of docetaxel and gemcitabine combination chemotherapy in non-small cell lung cancer patients failing previous chemotherapy. Am J Clin Oncol 25:509–512
Kouroussis C, Mavroudis D, Kakolyris S et al (2004) High incidence of pulmonary toxicity of weekly docetaxel and gemcitabine in patients with non-small cell lung cancer: results of a dose-finding study. Lung Cancer 44:363–368
Fernández Y, Esteban E, Villanueva J et al (2006) Prospective randomised phase II study of gemcitabine and vinorelbine versus gemcitabine and docetaxel combination in patients with previously untreated advanced non-small cell lung cancer. Proc Am Soc Clin Oncol 671:17052
McNeill G, Kalmadi S, Davis M et al (2006) Phase II trial of weekly docetaxel and gemcitabine as first line therapy for patients with advanced non-small cell lung cancer. Proc Am Soc Clin Oncol 673:17076
Popa IE, Stewart K, Smith FP, Rizvi NA (2002) A phase II trial of gemcitabine and docetaxel in patients with chemotherapy-naive advanced non-small cell lung carcinoma. Cancer 95:1714–1719
Onishi H, Kuriyama K, Yamaguchi M et al (2003) Concurrent two-dimensional radiotherapy and weekly docetaxel in the treatment of stage III non-small cell lung cancer: a good local response but no good survival due to radiation pneumonitis. Lung Cancer 40:79–84
Vergnenegre A, Daniel C, Lena H et al (2005) Docetaxel and concurrent radiotherapy after two cycles of induction chemotherapy with cisplatin and vinorelbine in patients with locally advanced non-small cell lung cancer. Lung Cancer 47:395–404
Jang TW, Park JP, Kim HK et al (2004) Concurrent docetaxel-cisplatin and thoracic radiotherapy for locally advanced non-small cell lung cancer. Tuberc Respir Dis 57:257–264
Sakai H, Yoneda S, Kobayashi K et al (2004) Phase II study of bi-weekly docetaxel and carboplatin with concurrent thoracic radiation therapy followed by consolidation chemotherapy with docetaxel plus carboplatin for stage III non-small cell lung cancer. Lung Cancer 43:195–201
Bedano PM, Neubauer M, Ansari R et al (2006) Phase III study of cisplatin plus etoposide with concurrent chest radiation followed by docetaxel vs. observation in patients with stage III non-small cell lung cancer: an interim toxicity analysis of consolidation therapy. Proc Am Soc Clin Oncol 374:7043
Gandara DR, Chansky K, Albain KS et al (2003) Consolidation docetaxel after concurrent chemoradiotherapy in stage III non-small-cell lung cancer: Phase II Southwest Oncology Group Study S9504. J Clin Oncol 21:2004–2010
Sekine I, Nokihara H, Sumi M et al (2006) Docetaxel consolidation therapy following cisplatin, vinorelbine and concurrent thoracic radiotherapy in patients with unresectable stage III non-small-cell lung cancer. J Thorac Oncol 8:810–815
Moon C, Verschraegen CF, Bevers M et al (2000) Use of docetaxel in patients with paclitaxel hypersensitivity. Anticancer Drugs 11:565
Denman JP, Gilbar PJ, Abdi EA (2002) Hypersensitivity reaction to docetaxel after a previous hypersensitivity reaction to paclitaxel. J Clin Oncol 20:2760
Chen YM, Shif JF, Perng RP et al (2006) A randomized trial of different docetaxel schedules in non-small cell lung cancer patients who failed previous platinum-based chemotherapy. Chest 129:1031–1038
(2006) Radiation-induced lung injury. UptoDate, version 14.3. Available at http://www.uptodate.com
Villanueva N, Esteban E, Muñiz I et al (2006) Weekly 70 Gy thoracic radiotherapy concurrent with docetaxel or paclitaxel alter induction chemotherapy of patients with locally advanced non-small cell lung cancer. Prospective study of tolerance and efficacy. Oncología 29:30–36
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Grande, C., Villanueva, M.J., Huidobro, G. et al. Docetaxel-induced interstitial pneumonitis following non-small-cell lung cancer treatment. Clin Transl Oncol 9, 578–581 (2007). https://doi.org/10.1007/s12094-007-0106-4
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s12094-007-0106-4